Bench to bedside review: Extracorporeal carbon dioxide removal, past present and future by Cove, ME et al.
Introduction
Th e reported incidence of acute respiratory distress 
syndrome (ARDS) ranges from 7 to 59 per 100,000 
people [1,2], and is associated with a mortality rate of 40 
to 45%. Th is rate remains unacceptably high despite the 
introduction of lung protective ventilation and, although 
hospital mortality may be slowly decreasing, ICU and 
28 day mortality have remained constant [1,3]. Failure to 
implement lung protective ventilation (LPV) may be one 
of the reasons ICU mortality rates have remained 
unchanged [4-6]. When surveyed, health care providers 
reported that hypercapnia or its related eﬀ ects were 
signiﬁ cant barriers to achieving LPV [7]. Hypercapnia 
complicated 14% of patients in the large ARDS network 
on the use of LPV [8]. However, patients with a high risk 
of death were excluded. In a study of severe ARDS, where 
tidal volumes were adjusted to target a mean airway 
pressure less than 28  cmH2O, all patients experienced 
hypercapnia [9]. As evidence emerges that tidal volumes 
<6 ml.kg-1 might further reduce mortality [9,10], alterna-
tive strategies to manage the inevitable hypercapnia must 
be considered.
Permissive hypercapnia is one approach, but it only 
improves mortality when patients are ventilated with 
high tidal volumes [8]. Such volumes should no longer be 
used since 6  ml.kg-1 is superior to 12  ml.kg-1 and 
<4 ml.kg-1 might be superior to 6 ml.kg-1 [9-11]. Although 
hypercapnia might have beneﬁ cial eﬀ ects on oxygen 
delivery and attenuation of inﬂ ammation [12], it also 
harms injured lung through immunosuppression and 
impaired pulmonary epithelial repair [13,14]. Further-
more, hypercapnia perpetuates right heart failure [15] 
and is undesirable in patients with elevated intracranial 
pressure. An alternative strategy to manage hypercapnia 
is extracorporeal carbon dioxide removal (ECCOR), a 
technology pioneered four decades ago [16] but only 
recently readily accessible through commercialization of 
several novel devices. ECCOR therefore deserves a fresh 
look and this review aims to provide an overview of 
devices currently available and those that may be 
available in the near future.
ECCOR in principle
ECCOR is designed to remove carbon dioxide (CO2) and, 
unlike extracorporeal membrane oxygen (ECMO), does 
not provide signiﬁ cant oxygenation. A discussion of 
ECMO is beyond the scope of this article but is well 
reviewed elsewhere [17,18]. In its simplest form, ECCOR 
consists of a drainage cannula placed in a large central 
vein, a pump, a membrane lung and a return cannula 
(Figure  1). Blood is pumped through the membrane 
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‘lung’ and CO2 is removed by diﬀ usion. Membrane lungs 
are permeable to gases but not liquids. A ﬂ ow of gas 
containing little or no CO2 runs along the other side of 
the membrane, ensuring the diﬀ usion gradient favors 
CO2 removal.
In contrast to ECMO, where the need for oxygenation 
requires high blood ﬂ ow rates, ECCOR allows much 
lower blood ﬂ ow rates, a result of major diﬀ erences in 
CO2 and oxygen (O2) kinetics. First, almost all the O2 in 
blood is carried by hemoglobin, which displays sigmoidal 
saturation kinetics. Assuming normal hemoglobin and 
venous O2, each liter of venous blood can only carry an 
extra 40 to 60  ml of O2 before the hemoglobin is satu-
rated. Blood ﬂ ows of 5 to 7  L.minute-1 are therefore 
required to supply enough O2 for an average adult (250 ml.
minute-1). Conversely, most CO2 is transported as 
dissolved bi carbo nate, displaying linear kinetics without 
saturation. Th us, 1 L of blood is capable of carrying more 
CO2 than O2, and 250  ml of CO2 can be removed from 
<1 L of blood. Second, CO2 diﬀ uses more readily than O2 
across extracorporeal membranes because of greater 
solubility [17].
The membrane lung
Th e membrane lung made long-term extracorporeal gas 
exchange feasible. Before membrane lungs, extracor por eal 
circuits achieved gas exchange by creating a direct air-
blood interface, either bubbling air through blood or 
creating a thin ﬁ lm of blood on the surface of a rotating 
cylinder/disc. However, blood-air interfaces denature 
proteins, activate clotting and inﬂ ammatory pathways, 
and damage circulating cells [19]. Consequently, devices 
relying on blood-air interfaces cannot be used more than 
a few hours without serious complications.
Th e concept of placing a barrier between blood and air 
began with the observation that gas exchange occurred 
across cellophane tubing in hemodialysis machines [20]. 
Th is led to the development of membrane lungs consist-
ing of gas permeable silicone-rubber mounted on a nylon 
mesh [21]. Th e nylon mesh provided structural strength 
and decreased leakage from random pinhole defects, 
which occur during the manufacture of thin silicone-
rubber membranes [19]. Th ree major factors determine 
the amount of gas crossing membranes: the diﬀ usion 
gradient, the membrane-blood contact time and the 
membrane diﬀ usion characteristics.
Th e CO2 diﬀ usion gradient is determined by the CO2 
content of the blood and the air passing through the 
membrane lung, as well as the speed of the airﬂ ow. 
Membrane-blood contact time is determined by mem-
brane geometry. In early devices, Th eodore Kolobow 
arranged the membrane into a coil [22] and used a fabric 
with an irregular surface, increasing the surface area [23]. 
Hollow ﬁ ber membranes have now replaced coiled 
silicon-rubber membranes. Early ﬁ bers were constructed 
with microporous polypropylene. Micropores create 
microscopic blood-gas interfaces allowing eﬃ  cient gas 
exchange, but also cause plasma leak. Recently, non-
microporous poly-4-methyl-1-pentene (PMP) has been 
used; it provides superior gas exchange, better bio com-
patibility and is less susceptible to plasma leak [24-26]. 
Adding covalently bound heparin to membrane surfaces 
enhances biocompatibility, and gas exchange has been 
improved by arranging ﬁ bers into a complex mat and 
running blood on the outside [27] (Figure  2). Th is 
arrange ment allows perpendicular blood ﬂ ow to the 
ﬁ bers, improving mass transfer by reducing the diﬀ usion 
path length compared to parallel ﬂ ow. Modern 
membrane lungs achieve adequate gas exchange with 
surface areas of 1 to 3 m2 (Table 1).
The pump
Blood ﬂ ow through ECCOR circuits can be achieved in 
one of two ways. In patients with suﬃ  cient arterial 
pressure, a pumpless system can be used where blood is 
driven out of an arterial cannula by high arterial pressures 
and returned through a venous cannula, often called 
arterio venous CO2 removal (AVCO2R). Pumpless systems 
result in less blood trauma, but require large bore arterial 
cannulas and an adequate cardiac output. Th e alternative 
is to use a mechanical pump.
Early devices used roller or peristaltic pumps. Although 
cheap and reliable, these pumps were prone to blood 
trau ma - for example, hemolysis - from compression and 
heating of blood components. Blood trauma is less of a 
problem at lower blood ﬂ ow rates - for example, those 
used in dialysis. Th e introduction of rotary pumps has 
resulted in simpler yet eﬀ ective systems that cause less 
blood trauma. Two main types of rotary pumps are used 
in ECCOR devices, centrifugal and diagonal ﬂ ow pumps. 
Figure 1. Diagram demonstrating essential components of an 
extracorporeal carbon dioxide removal circuit.
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Centrifugal pumps use a radial rotating impeller to create 
a suction vortex that draws blood into the center of the 
pump and spins it outwards, imparting centrifugal 
momentum, which is converted into driving pressure. In 
diagonal ﬂ ow pumps, impellor design is a mix of radial 
and axial geometry. Centrifugal pumps tend to generate 
high pressures and low ﬂ ows, whereas diagonal pumps 
produce both high ﬂ ows and high pressures [28]. 
Impellors are connected to a drive shaft, requiring bear-
ings to support the rotational movement. Exposure of 
blood to typical bearings promotes clotting, causing 
depo sition of coagulation debris that can seize the bear-
ing. Some pumps use seals to protect the bearings, but 
these can wear out; other designs use biocompatible 
materials to construct the bearings. In the most advanced 
centrifugal pumps impellors are completely suspended in 
an electromagnetic ﬁ eld, eliminating the need for a drive 
shaft or bearings and reducing heating, minimizing blood 
trauma and lowering the incidence of mechanical failure.
Access cannula
Early clinical trials placed separate drainage and return 
cannulas in the saphenous veins [29,30]. Modern cannulas 
are placed percutaneously in a femoral-femoral or femoral-
jugular orientation. To maintain ﬂ ow and minimize blood 
trauma, heparin-coated wire-reinforced cannulas are 
used. Recently, a high ﬂ ow, wire-reinforced double-
lumen catheter has been developed. It is placed via the 
right internal jugular vein and the drainage port (tip of 
the cannula) is advanced into the intra-hepatic inferior 
vena cava using ultrasound guidance [31]. In this 
orientation the return port aligns with the right atrium, 
minimizing recirculation. New ECCOR devices with ﬂ ow 
rates comparable to those in dialysis use double-lumen 
cannulas similar to dialysis catheters [32,33].
ECCOR in practice
Th e ﬁ rst clinica l trial of extracorporeal respiratory 
support was published in 1979, and used the Kolobow 
spiral-coil membrane lung, a roller pump and veno-
arterial access to provide ECMO [34]. Th is trial found no 
diﬀ erence between conventional treatment and ECMO. 
At about the same time Gattinoni and coworkers 
introduced ECCOR [35], but did not publish the ﬁ rst 
clinical trial until 1986, where patients with severe ARDS 
were selected for LPV combined with ECCOR (Kolobow 
spiral-coil membrane lung, and a roller pump). Observed 
mortality was 51% using this technique [29]. Subsequent 
work was initially encouraging [36] but a randomized 
controlled study in 1994 concluded that ECCOR con-
ferred no survival advantage [30]. Importantly, compli-
cation rates were high with ECCOR, being discontinued 
in 33% of cases owing to bleeding, and 20% experiencing 
circuit clotting. Recently, new devices with lower compli-
cation rates have demonstrated improved survival when 
combined with ultra-protective ventilation [9]; some are 
already available whilst others are in advanced develop-
ment. Th ey can be broadly categorized into 
i)  arteriovenous devices, ii)  venovenous devices, iii) gas 
exchange catheters and iv) respiratory dialysis.
Figure 2. Diagram showing the basic principle of a membrane lung. Sweep gas passes through the hollow fi bres. Hollow fi bers are arranged in 
a complex mat. Image courtesy of Medos Medizintechnik AG (Stolberg, Germany).
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Arteriovenous carbon dioxide removal
AVCO2R is commercially available through Novalung 
(GmbH, Hechingen, Germany) and marketed as the 
interventional lung assist (iLA) membrane ventilator 
(Figure  3). Th e membrane lung, frequently called the 
‘Novalung’, utilizes a low resistance design allowing blood 
ﬂ ow using the patient’s own arteriovenous pressure 
gradient. Cannulas are placed percutaneously in the 
femoral artery and vein [37,38]. A similar system has 
been developed in the United States using the Aﬃ  nity 
NT (Medtronic, Minneapolis, MN) [39,40].
Pumpless systems require an arteriovenous pressure 
gradient ≥60 mmHg, which is unsuitable for hemo dynami-
cally unstable patients. Further, cannulation of a major 
artery can result in distal ischemia [37], although measuring 
the artery diameter with ultrasound and selecting a cannula 
that occupies no more than 70% of the lumen reduces this 
risk [38]. AVCO2R has been successfully used to facilitate 
LPV in patients with ARDS [41-43], severe asthma [44] and 
as a bridge to lung trans plantation [45].
Venovenous carbon dioxide removal
Venovenous carbon dioxide removal (VVCO2R) requires 
a mechanical pump to propel blood through the circuit 
and  can be broadly divided depending on whether the 
pump and membrane lung are separate components or 
incorporated into a single console. When separate 
components are used, the circuit is set up as described in 
Figure 1. Table 1 shows some of the diﬀ erent components 
that can be used. Th ese circuits are more complicated to 
operate, often need ﬂ ow rates >1  L.minute-1 and may 
need multidisciplinary support. Th e growth of programs 
in more general settings has provided impetus to simplify 
ECCOR, resulting in several devices where the pump and 
membrane lung are combined into one console.
iLA Activve
Th e iLA Activve mounts the Novalung and a diagonal 
ﬂ ow pump together in one device. At higher blood ﬂ ow 
rates this device can provide venovenous ECMO. 
Conceptually, this is the simplest method of providing 
ECCOR via a console, and although it does not provide 
any special beneﬁ ts over separate components, the pump 
is designed to provide reliable ﬂ ows throughout a large 
range of ﬂ ow rates.
Decap/Decapsmart
Th e Decap system (Hemodec, Salerno, Italy) uses a 
membrane lung in series with a hemodialysis ﬁ lter and 
roller pump (Figure 4). Th e hemodialysis ﬁ lter serves two 
purposes with regard to CO2 removal. First, it reduces 
the chance of bubble formation by increasing resistance 
within the membrane lung. Second, ultraﬁ ltrate from the 
ﬁ lter is returned to the blood stream prior to the mem-
brane lung inﬂ ow. Since ultraﬁ ltrate contains dissolved 
CO2, recirculating in this way allows additional CO2 
removal by creating a greater ﬂ ow rate through the 
membrane lung than the ﬂ ow from the patient. Conse-
quently, smaller membrane lungs can be used (0.3 to 
1.35  m2) with lower ﬂ ow rates (<500  ml.minute-1) than 
conventional ECCOR [33], resulting in similar anti coagu-
lation requirements to continuous venovenous hemo-
dialysis [46]. Th e Decap has been successfully used in 
adults and children [9,47,48].
Hemolung
Th e Hemolung (Alung Technologies, Pittsburgh, USA) is 
the latest device to enter the ECCOR arena. In this device 
the membrane lung and centrifugal pump are combined 
together, acting as one unit (Figure  5). Blood is drawn 
into the unit via a rotating impeller. Th e center contains a 
rotating core that accelerates blood towards a surround-
ing stationary ﬁ ber bundle. Th is is called active mixing; 
the rotating core generates disturbed blood ﬂ ow patterns 
subjacent to the ﬁ ber membrane, reducing diﬀ usional 
resistance and increasing gas exchange. As a result, CO2 
removal is more eﬃ  cient and achieved with a smaller mem-
brane surface area and ﬂ ows of 400 to 600  ml.minute-1, 
Table 1. Extracorporeal carbon dioxide removal circuit components
Component Name Special features Manufacturer
Pump Centrimag Impeller elevated in electromagnetic fi eld Levotronix LLC Waltham, MA, USA
 RotaFlow Impeller driven by electromagnetic fi eld and has single  Maquet, Rastatt, Germany
  sapphire bearing
 Biomedicus Impeller drive shaft supported by sealed bearings Medtronic, Eden Praire, MN, USA
 Deltastream Diagonally streamed impeller, sealed bearings Medos Medizintechnik AG, Stolberg, Germany
Membrane lung Quadrox D 1.8 m2 surface area, 250 ml priming volume Maquet, Rastatt, Germany
 iLA membrane ventilator 1.3 m2 surface area, 175 ml priming volume Novalung GmbH, Heilbronn, Germany
 hilite 7000LT 1.9 m3 surface area, 275 ml priming volume Medos Medizintechnik AG, Stolberg, Germany
 Affi  nity NT 2.5 m2 surface area, 270 ml priming volume Medtronic, Eden Praire, MN, USA
This list is not exhaustive, but demonstrates the range of products available. iLA, interventional lung assist.
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which allows use of smaller double-lumen catheters. Th e 
smaller membrane surface area, siloxane coating for 
plasma resistance and covalently bound heparin result in 
lower anticoagulation requirements [32]. Gas ﬂ ow 
through the membrane lung is supplied under negative 
pressure, a safety feature preventing air embolism if the 
membrane is disrupted. Th e Hemolung enabled a 50% 
reduction in minute ventilation in animal trials and was 
recently successfully used in a clinical case series of ﬁ ve 
adults [49].
Gas-exchange catheters
Several gas-exchange catheters have been developed but 
only one, the intravenocaval oxygenator and carbon 
dioxide removal device (IVOX), has been used clinically. 
Th ese devices package hollow ﬁ ber membrane lungs into 
a catheter that is small enough to be placed in the vena 
cava, that is, <15 mm in diameter. Intracorporeal catheters 
are conceptually attractive because they are exposed to 2 
to 3 L.minute-1 of blood ﬂ ow and therefore CO2 removal 
is not ﬂ ow limited.
Th e IVOX was designed for both oxygenation and CO2 
removal. Orienting ‘crimped’ membrane ﬁ bers in a spiral 
arrangement maximized gas exchange by increasing 
surface area and creating disturbed blood ﬂ ow patterns 
over the membrane [50]. Disturbed blood ﬂ ow provides 
convection velocity towards the ﬁ ber surfaces, reducing 
diﬀ usional resistance. Th e membrane surface of the 
IVOX ranged from 0.2 to 0.5  m2 [51] and gas ﬂ ow was 
applied under negative pressure; an important safety 
feature in intracorporeal devices since there is no other 
opportunity to prevent air embolism if the membrane is 
disrupted.
In animal trials the IVOX consistently removed 
40  ml.minute-1 of CO2, but oxygen delivery was less 
reliable. Clinical experience was mixed; the IVOX 
facilitated lower ventilator settings in some studies [52], 
but made no diﬀ erence in others [53,54]. On the whole, 
gas exchange was too limited and placement associated 
with high complication rates from bleeding and throm bosis 
[52]. Commercial development has subsequently ceased.
Future directions and devices in development
Several of the above devices are undergoing clinical trials, 
often in combination with LPV (Table 2). Other promis-
ing approaches are still in development, in particular 
more eﬃ  cient gas exchange catheters and respiratory 
dialysis. Novel methods to maximize CO2 removal, such 
as blood acidiﬁ cation, are also under investigation [55].
Gas-exchange catheters in development
Following the IVOX, attention has focused on developing 
a catheter that meets 50% of adult gas exchange require-
ment. Several ingenious approaches are being studied. 
Th e ﬁ rst approach is generation of active mixing within 
the catheter. Th is was initially attempted using an intra-
aortic balloon pump close to the shaft of the IVOX 
catheter [56]. However, the membrane ﬁ bers were not 
ﬁ xed and ﬁ ber movement opposed active mixing. Th e 
Hattler catheter solved this using a rigid ﬁ ber mat 
constructed around a central balloon [57] (Figure  6). 
Rapid pulsation of the balloon directed blood ﬂ ow over 
the membrane ﬁ bers, causing active mixing. In this 
design membrane ﬁ bers do not occupy the whole lumen 
of the vein, causing less ﬁ ber drag on blood ﬂ ow. In 
animal trials the Hattler catheter exchanged CO2 at 
305  ml.minute-1.m-2, almost double the IVOX rate at 
similar CO2 concentrations [58,59].
Figure 3. Image of the interventional lung assist (iLA), blood is 
propelled through the circuit by arterial pressure. Image courtesy 
of Novolung (GmbH, Hechingen, Germany).
Figure 4. Diagram showing the basic circuit design of the Decap 
(Hemodec, Salerno, Italy). Blood is pumped through a membrane 
lung in series with a dialysis fi lter, and ultrafi ltrate is returned to the 
blood prior to the membrane. UF, ultrafi ltrate.
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Active mixing can also be achieved by rotating the ﬁ ber 
bundle; a strategy used in the dynamic intravascular lung 
assist device (D-ILAD) [60]. Although the D-ILAD was 
almost twice as eﬃ  cient as balloon-pulsating catheters, 
rotating ﬁ bers could damage vessel walls upon contact. 
Recently, the Hattler catheter has been modiﬁ ed by 
replacing the balloon with a series of small impellers. It 
has been successfully used in animals and has CO2 
exchange rates similar to the D-ILAD [61].
Finally, in addition to active mixing, CO2 exchange has 
been improved by covalent immobilization of carbonic 
anhydrase to the surface of the hollow ﬁ ber membrane 
[62]. As a result, CO2 is more rapidly generated from 
bicarbonate, facilitating removal.
Respiratory dialysis
In the 1980s, several groups reported the results of 
animal experiments using dialysis to remove CO2 in the 
form of bicarbonate. Th is approach is appealing because 
CO2 is transported in the form of bicarbonate, which 
moves freely across dialysis membranes. Conventional 
hemodialysis uses bicarbonate-containing dialysates to 
correct the metabolic acidosis accompanying renal failure, 
but bicarbonate-free dialysates can remove enough CO2 
to replace pulmonary ventilation in dog models [63]. 
Currently, respiratory dialysis is limited by the inability to 
maintain electrolyte concentrations and pH whilst 
removing bicarbonate. Several approaches to replace bi-
carbonate have been attempted using sodium hydroxide, 
tromethamine (THAM), and organic anions. However, 
ﬂ uid gain, hyperchloremic acidosis, hemolysis, cardiac 
arrhythmias and acid-base derangements have prevented 
successful long-term use [64,65].
Recently, hemoﬁ ltration has been used to remove 
bicarbonate. One group used sodium hydroxide in a 
post-ﬁ lter replacement ﬂ uid and maintained pH and CO2 
Figure 5. Cross sectional diagram of Hemolung (Alung Technologies, Pittsburgh, USA) showing rotating core that accelerate blood to the 
surrounding fi ber bundle. Adjacent image shows the Hemolung console. Courtesy of Alung Technologies (Pittsburgh, USA).
Table 2. Current active trials from clinicaltrials.gov accessed April 2012
Study title Device Sponsor Status
Extracorporeal CO2 removal in COPD (DECOPD) Decap Smart University of Turin, Italy Recruiting
Pulmonary and Renal Support during Acute  Neonatal membrane lung (HiLite 800 LT,  Hopital Ambroise Pare, France Recruiting
Respiratory Distress Syndrome (PARSA) Medos) within dialysis circuit (Multifi ltrate kit 7, 
 CVVH 1000, Fresenius)
Low-fl ow ECCO2-R and 4 ml/kg Tidal Volume  Not specifi ed University of Turin, Italy Not yet recruiting
vs. 6 ml/kg Tidal Volume to Enhance Protection 
From Ventilator Induced Lung Injury in Acute 
Lung Injury (ELP)
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within physiological range for 18 hours in hypoventilated 
sheep. However, hyperchloremic acidosis developed and 
blood ﬂ ow rates exceeding 500  ml.minute-1 would be 
needed to remove suﬃ  cient CO2 in humans [66]. Another 
group removed bicarbonate by using pre-ﬁ lter replace-
ment ﬂ uid containing THAM. Physiologic CO2 levels and 
pH were maintained for 1.5 hours, but it was not deter-
mined whether THAM had the same long-term problems 
seen in the hemodialysis models [67]. Nonetheless, 
respiratory dialysis holds much promise if the problems 
of electrolyte and acid-base disturbances can be solved.
Conclusion
Several modalities of providing ECCOR are now either 
available or in development. As evidence favoring low-
volume, low-pressure ventilation in ARDS accumulates, 
the argument for applying these ventilation strategies in 
all critically ill patients will gather momentum. However, 
successful application is dependent upon a safe, reliable 
approach for CO2 removal.
Simpler more eﬃ  cient ECCOR devices requiring lower 
blood ﬂ ow rates and smaller access cannulas promise to 
improve safety and ease of use. Novel designs, such as the 
Decap, can serve the dual purpose of renal support and 
ECCOR. However, other solutions currently in develop-
ment, gas exchange catheters and respiratory dialysis, 
promise to be minimally invasive, easy to initiate and well 
tolerated. Th ey may even eliminate the need for intuba-
tion in some forms of respiratory failure, where CO2 is 
the primary problem [68]. Familiarity with devices already 
available can change our approach to ARDS and prime 
the ICU for the arrival of devices that may revolutionize 
our approach to respiratory failure.
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